Catalent has entered into an agreement with Triphase Accelerator Corporation, a Toronto-based company acquiring and developing cancer therapeutics, in which Triphase will obtain worldwide rights to further develop Catalent’s proprietary antibody drug conjugate (ADC), CD22-4AP. The ADC was developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, using Redwood Bioscience’s SMARTag technology platform. The SMARTag technology platform enables a simple chemoenzymatic approach for generating uniform ADCs, according to Catalent.

Catalent will receive an upfront payment and has the potential to earn additional development and commercial milestone payments, plus a royalty on product sales. Triphase will also contract with Catalent for development, manufacturing, and analytical services.

CD22-4AP is a site-specific ADC, targeting CD22, a B-cell-restricted sialoglycoprotein that is a modulator of B-cell signaling and survival. CD22 is being developed for Non-Hodgkin`s lymphoma and acute lymphoid leukemia.

Source: Catalent